Every Form 4 that Humacyte Inc (HUMA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow HUMA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HUMA filings page.
Humacyte, Inc. (HUMA) director Keith Anthony Jones reported purchasing 10,000 shares of Humacyte common stock in an open market or private transaction on August 20, 2026 at a price of $0.693 per share. Following this transaction, he directly owns 40,000 shares of Humacyte common stock.
Humacyte, Inc. (HUMA) director Keith Anthony Jones purchased Humacyte common stock in the open market. On 2026-08-17, he bought 30,000 shares at a weighted average price of about $0.594 per share, resulting in direct holdings of 30,000 shares.
Humacyte, Inc. director Susan Richards Windham-Bannister received a grant of stock options covering 80,000 shares of common stock. The options carry an exercise price of 1.08 per share and expire on June 11, 2036.
According to the vesting terms, 25% of the option becomes exercisable on June 11, 2027. The remaining portion vests in equal monthly installments, with 1/48 of the option becoming exercisable on the 11th of each month through June 11, 2030. Following this grant, she holds 80,000 stock options directly.
Humacyte, Inc. director Michael T. Constantino received a grant of stock options covering 80,000 shares of Common Stock. The options have an exercise price of $1.08 per share and expire on June 11, 2036. The first 25% vests on June 11, 2027, with the remaining portion vesting in equal monthly installments through June 11, 2030.
Humacyte, Inc. director Max N. Wallace received a grant of stock options for 80,000 shares of Common Stock. The options carry an exercise price of $1.08 per share and expire on June 11, 2036. Following this grant, he holds stock options covering 80,000 underlying shares.
The vesting is time-based: the first 25% of the option becomes exercisable on June 11, 2027, and the remaining portion vests in equal monthly installments (1/48 of the option) on the 11th of each month through June 11, 2030. This is a compensation-related award, not an open-market purchase or sale.
Humacyte, Inc. reported that President and CEO Laura E. Niklason had an indirect acquisition of stock options through her spouse. The grant covers 80,000 stock options for Humacyte common stock at an exercise price of $1.08 per share, expiring on June 11, 2036. According to the vesting schedule, the first 25% of the option becomes exercisable on June 11, 2027, and the remaining portion vests in equal monthly installments on the 11th of each month through June 11, 2030.
Humacyte, Inc. director Kathleen Sebelius reported a grant of stock options representing the right to buy 80,000 shares of common stock. The options have an exercise price of $1.08 per share and expire on June 11, 2036.
According to the vesting terms, the first 25% of the option becomes exercisable on June 11, 2027, and the remaining portion vests in equal monthly installments on the 11th of each month through June 11, 2030. Following this grant, Sebelius holds 80,000 stock options directly.
Humacyte, Inc. director Keith Anthony Jones received a grant of stock options for 80,000 shares of Common Stock. The options were awarded at an exercise price of $1.08 per share and are held directly. Following the grant, Jones holds 80,000 stock options.
According to the vesting terms, the first 25% of the option becomes exercisable on June 11, 2027. After that date, 1/48 of the option vests on the 11th of each month through June 11, 2030, with the option expiring on June 11, 2036. This is a compensation-related award rather than an open-market purchase or sale.
Humacyte, Inc. director Charles Bruce Green received a grant of stock options covering 80,000 shares of common stock. The options have an exercise price of $1.08 per share and expire on June 11, 2036. Following this grant, he holds 80,000 stock options directly.
According to the vesting terms, the first 25% of the option becomes exercisable on June 11, 2027, and the remaining portion vests in equal monthly installments through June 11, 2030. This is a compensation-related award rather than an open-market share purchase or sale.
Humacyte director Diane Seimetz received a grant of stock options covering 80,000 shares of common stock. The options have an exercise price of $1.08 per share and expire on June 11, 2036. This is a compensation-related award, not an open-market purchase. Following the grant, she holds options on 80,000 shares directly. The footnote states that 25% of the options vest on June 11, 2027, with the remainder vesting in equal monthly installments through June 11, 2030.
Humacyte, Inc. reported that director John Philip Bamforth received a grant of stock options covering 80,000 shares of common stock. The options have an exercise price of $1.08 per share and expire on June 11, 2036. Following this grant, he holds 80,000 options directly.
The footnote explains that 25% of the options become exercisable on June 11, 2027, with the remaining portion vesting in equal monthly installments (1/48 of the grant) on the 11th of each month through June 11, 2030. This is a compensation-related award rather than an open-market purchase.
Humacyte, Inc. director Emery N. Brown received a grant of stock options covering 80,000 shares of common stock at an exercise price of 1.08 per share. The options expire on June 11, 2036. One quarter vests on June 11, 2027, with the remainder vesting monthly through June 11, 2030.
Humacyte, Inc. director Brady W. Dougan received a grant of stock options to acquire common shares. The award covers options exercisable for 80,000 shares of Humacyte common stock at an exercise price of $1.08 per share, expiring on June 11, 2036.
The options were granted as compensation and do not reflect an open-market purchase or sale. According to the vesting terms, 25% of the options become exercisable on June 11, 2027, with the remaining options vesting in equal monthly installments through June 11, 2030.
Humacyte, Inc. director Kathleen Sebelius reported an open-market purchase of 56,818 shares of Humacyte common stock at a price of $0.88 per share on May 19, 2026. Following this transaction, she directly holds a total of 148,025 Humacyte common shares.
Humacyte, Inc. director Michael T. Constantino reported an open-market purchase of common stock. On May 18, 2026, he bought 11,000 shares of Humacyte common stock at a weighted average price of $0.8945 per share in multiple transactions.
Following this purchase, Constantino directly owns 43,950 common shares. The filing notes that the trades were executed across a price range from $0.8922 to $0.8958 per share and that detailed trade-by-trade pricing is available upon request.
Humacyte, Inc. CFO and Chief Corporate Development Officer Dale A. Sander reported an automated sale of 45,887 shares of common stock at an average price of $0.8967 per share. The sale was executed solely to cover statutory tax withholding from vested restricted stock units under a pre-arranged Rule 10b5-1 sell-to-cover plan, not as a discretionary sale. After this transaction, he holds 267,213 shares directly and 40,600 shares indirectly through his spouse.
Humacyte, Inc.'s Chief Medical Officer, Shamik J. Parikh, reported an automated sale of 45,887 shares of common stock at an average price of $0.8967 per share.
The filing explains this was a mandatory “sell-to-cover” transaction to fund statutory tax withholding tied to vesting of restricted stock units, carried out under a Rule 10b5-1(c) trading plan and not a discretionary sale. After this tax-related sale, Parikh directly holds 272,713 shares of Humacyte common stock.
Humacyte, Inc. (HUMA) reported an equity award to a senior executive. The company’s CFO and Chief Corporate Development Officer, Dale A. Sander, reported acquiring 311,100 shares of Humacyte common stock on 11/16/2025 at a reported price of $0, reflecting a grant rather than an open-market purchase. Following this transaction, he beneficially owns 313,100 shares directly and 40,600 shares indirectly through his spouse.
The filing explains that these shares relate to restricted stock units (RSUs). The RSUs represent the right to receive one share of common stock for each unit, with 50% scheduled to vest on May 15, 2026 and the remaining 50% on May 15, 2027. This structure ties a significant portion of the executive’s compensation to the company’s future share performance over a two-year vesting period.
Humacyte, Inc. (HUMA) reported an equity award to its Chief Medical Officer, Shamik J. Parikh, on a Form 4. On 11/16/2025, Parikh acquired 311,100 shares of Humacyte common stock at a stated price of $0, linked to a grant of restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of common stock. The first 50% of these RSUs will vest on May 15, 2026, with the remaining 50% vesting on May 15, 2027, subject to the award’s conditions. Following this reported transaction, Parikh beneficially owns 318,600 shares of Humacyte common stock, held directly.
Humacyte, Inc. (HUMA) reported a Form 4 for a director showing an indirect grant of stock options held by the director’s spouse. On 11/16/2025, the spouse acquired 311,100 stock options$1.23 per share
According to the vesting schedule, the first one-third of the options becomes exercisable on February 14, 2026, the next one-third on November 16, 2026, and the final one-third on November 16, 2027. Following this grant, the reporting person indirectly beneficially owns 311,100 derivative securities through the spouse.
Humacyte, Inc. (HUMA) reported a stock option award to its President, CEO and Director, Laura E. Niklason. On November 16, 2025, she was granted stock options to purchase 311,100 shares of Humacyte common stock at an exercise price of $1.23 per share, expiring on November 16, 2035. The options vest in three equal installments: one-third becomes exercisable on February 14, 2026, another third on November 16, 2026, and the final third on November 16, 2027. Following this grant, she holds these derivative securities directly.